Amolimogene + Amolimogene
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Dysplasia
Conditions
Uterine Cervical Dysplasia
Trial Timeline
Jul 1, 2005 → May 1, 2009
NCT ID
NCT00264732About Amolimogene + Amolimogene
Amolimogene + Amolimogene is a phase 2/3 stage product being developed by Eisai for Uterine Cervical Dysplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00264732. Target conditions include Uterine Cervical Dysplasia.
What happened to similar drugs?
4 of 18 similar drugs in Uterine Cervical Dysplasia were approved
Approved (4) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00264732 | Phase 2/3 | Completed |
Competing Products
20 competing products in Uterine Cervical Dysplasia